Updated with additional information.

Nine months of treatment with an experimental pill from Madrigal Pharmaceuticals resulted in the significant reversal of the fatty liver disease known as NASH, according to updated data from a placebo-controlled clinical trial released Thursday.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Isn’t that a rather large increase in share value for results in a phase 2? There’s still a long road to the market. This seems consistent with other Stat reports on excessive enthusiasm of the biotech investment community.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy